Amarantus to Present at LD Micro Invitational on June 4th
June 02 2014 - 8:13AM
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology
company focused on the discovery and development of novel
diagnostics and therapeutics related to endoplasmic reticulum
stress, cell cycle dysregulation, neurodegeneration and apoptosis,
today announced that Gerald E. Commissiong, President and CEO will
present at the LD Micro Invitational on Wednesday, June 4th, 2014
at the Luxe Sunset Boulevard Hotel in Los Angeles.
Mr. Commissiong's presentation will begin at 11:00 AM PST
/ 2:00 PM EST in Track One.
"We are honored to have Amarantus present at the conference,"
stated Chris Lahiji, President of LD Micro.
Attendees who wish to meet with management one on one may
contact the conference organizers or our Investor Relations
department at ir@amarantus.com. To learn more about LD MICRO and
the LD MICRO Invitational, please visit www.ldmicro.com.
About Amarantus
Amarantus is a biotechnology company developing treatments and
diagnostics for diseases associated with neurodegeneration and
protein misfolding-related apoptosis. The Company has licensed
Eltoprazine a phase 2b ready indication for Parkinson's Levodopa
induced dyskinesia. The Company has an exclusive worldwide license
to the Lymphocyte Proliferation test ("LymPro Test®") for
Alzheimer's disease and owns the intellectual property rights to a
therapeutic protein known as Mesencephalic-Astrocyte-derived
Neurotrophic Factor ("MANF") and is developing MANF-based products
as treatments for brain disorders. Amarantus is a Founding Member
of the Coalition for Concussion Treatment (#C4CT), a movement
initiated in collaboration with Brewer Sports International seeking
to raise awareness of new treatments in development for concussions
and nervous-system disorders. The Company also owns intellectual
property for the diagnosis of Parkinson's disease ("NuroPro") and
the discovery of neurotrophic factors ("PhenoGuard"). For further
information please visit www.Amarantus.com, or connect with the
Company on Facebook, LinkedIn, Twitter and Google+.
About LD Micro
LD Micro is a newsletter firm that focuses on finding
undervalued companies in the micro-cap space. Since 2002, the firm
has published reports on select companies throughout the year. LD
Micro concentrates on finding, researching, and investing in
companies that are often overlooked by institutional investors. It
is a non-registered investment advisor. For more information on the
list of presenting companies or to register for the event, please
visit http://www.ldmicro.com or call (408)
457-1042.
Certain statements, other than purely historical information,
including estimates, projections, statements relating to our
business plans, objectives, and expected operating results, and the
assumptions upon which those statements are based, are
forward-looking statements." These forward-looking statements
generally are identified by the words believes," project,"
expects," anticipates," estimates," intends," strategy," plan,"
may," will," would," will be," will continue," will likely result,"
and similar expressions. Forward-looking statements are based on
current expectations and assumptions that are subject to risks and
uncertainties which may cause actual results to differ materially
from the forward-looking statements. Our ability to predict results
or the actual effect of future plans or strategies is inherently
uncertain. Factors which could have a material adverse effect on
our operations and future prospects on a consolidated basis
include, but are not limited to: changes in economic conditions,
legislative/regulatory changes, availability of capital, interest
rates, competition, and generally accepted accounting principles.
These risks and uncertainties should also be considered in
evaluating forward-looking statements and undue reliance should not
be placed on such statements.
CONTACT: Investor/Media Contacts
Aimee Boutcher, Director of Investor Relations
Amarantus Bioscience Holdings, Inc.
408-737-2734 x 101
ir@amarantus.com
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Apr 2024 to May 2024
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From May 2023 to May 2024